Mechanism of inhibition of protein-tyrosine phosphatases by disodium aurothiomalate

Biochemical Pharmacology

Volumn 54, Issue 6, 1997, Pages 703-711

  Wang, Qingping ^a   Janzen, Nicole ^b   Ramachandran, Chidambaram ^a   Jirik, Frank ^b  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

BIAcore analysis; Drug inhibition; Enzyme kinetics; Gold; Protein tyrosine phosphatase; Rheumatoid arthritis

Indexed keywords

AUROTHIOMALATE; DITHIOTHREITOL; PROTEIN TYROSINE PHOSPHATASE;

ARTICLE; DRUG MECHANISM; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANTIGENS, CD45; BINDING, COMPETITIVE; ENZYME INHIBITORS; GLUTATHIONE TRANSFERASE; GOLD SODIUM THIOMALATE; PAPAIN; PROTEIN-TYROSINE-PHOSPHATASE; RECOMBINANT FUSION PROTEINS;

EID: 0030882583     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00217-7     Document Type: Article

References (48)

1. Klippel JH and Dieppe PA, Rheumatology. Mosby-Year Book, United Kingdom, 1994.
2. Lichtenstein LM and Fauci AS, Current Therapy in Allergy, Immunology, and Rheumatology, 4th Edn. Mosby-Year Book, New York, 1992.
3. Bochner BS, Undem BJ and Lichtenstein LM, Immunological aspects of allergic asthma. Annu Rev Immunol 12: 295-335, 1994.
4. Honma M, Tamura G, Shirato K and Takashima T, Effect of an oral gold compound, auranofin, on non-specific bronchial hyperresponsiveness in mild asthma. Thorax 49: 649-651, 1994.
5. Sanders KM, Carlson PL and Littman BH, Effects of gold sodium thiomalate on interferon stimulation of C2 synthesis and HLA-DR expression by human monocytes. Arthritis Rheum 30: 1032-1039, 1987.
6. Parente JE, Walsh MP, Girard PR, Kuo JF, Ng DS and Wong K, Effects of gold coordination complexes on neutrophil function are mediated via inhibition of protein kinase C. Mol Pharmacol 35: 26-33, 1989.
7. Lazarevic MB, Yan K, Swedler WI, Rasenick MM and Skosey JL, Effect of gold compounds on the activity of adenylyl cyclase in human lymphocyte membranes. Arthritis Rheum 35: 857-864, 1992.
8. Shaw CF, The mammalian biochemistry of gold: An inorganic perspective of chrysotherapy. Inorg Perspect Biol Med 2: 287-355, 1979.
9. 4+ T cell recognition of peptides containing two or more cysteine residues. J Immunol 155: 1575-1587, 1995.
10. Handel ML, deFazio A, Watts CK, Day RO and Sutherland RL, Inhibition of DNA binding and transcriptional activity of a nuclear receptor transcription factor by aurothiomalate and other metal ions. Mol Pharmacol 40: 613-618, 1991.
11. Tanaka H, Makino Y, Wright KD, Gustafsson JA, Okamoto K and Makino I, Zinc ions antagonize the inhibitory effect of aurothiomalate on glucocorticoid receptor function at physiological concentrations. Mol Pharmacol 48: 938-945, 1995.
12. Handel ML, Watts CKW, deFazio A, Day RO and Sutherland RL, Inhibition of AP-1 binding and transcription by gold and selenium involving conserved cysteine residues in Jun and Fos. Proc Natl Acad Sci USA 92: 4497-4501, 1995.
13. Yang J-P, Merin JP, Nakano T, Kato T, Kitade Y and Okamoto T, Inhibition of the DNA-binding activity of NF-κB by gold compounds in vitro. FEBS Lett 361: 89-96, 1995.
14. Hollywood DP and Hurst HC, Targeting gene transcription: A new strategy to down-regulate c-erbB-2 expression in mammary carcinoma. Br J Cancer 71: 753-757, 1995.
15. Rosenberg SA and Lipsky PE, Inhibition of pokeweed mitogen-induced immunoglobulin production in humans by gold compounds. J Rheumatol Suppl 5: 107-111 1979.
16. Hashimoto K, Whitehurst CE and Lipsky PE, Synergistic inhibition of T cell proliferation by gold sodium thiomalate and auranofin. J Rheumatol 21: 1020-1026, 1994.
17. Matsubara T and Ziff M, Inhibition of human endothelial cell proliferation by gold compounds. J Clin Invest 79: 1440-1446, 1987.
18. Wolf RE and Hall VC, Inhibition of in vitro proliferative response of cultured T lymphocytes to interleukin-2 by gold sodium thiomalate. Arthritis Rheum 31: 176-181, 1988.
19. Trowbridge IS and Thomas ML, CD45: An emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Annu Rev Immunol 12: 85-116, 1994.
20. Benatar T, Carsetti R, Furlonger C, Kamalia N, Mak T and Paige CJ, Immunoglobulin-mediated signal transduction in B cells from CD45-deficient mice. J Exp Med 183: 329-334, 1996.
21. Berger SA, Mak TW and Paige CJ, Leukocyte common antigen (CD45) is required for immunoglobulin E-mediated degranulation of mast cells. J Exp Med 180: 471-476, 1994.
22. Stone RL and Dixon JE, Protein-tyrosine phosphatases. J Biol Chem 269: 31323-31326, 1994.
23. Huyer G, Li ZM, Adam M, Huckle WR and Ramachandran C, Direct determination of the sequence recognition requirements of the SH2 domains of SH-PTP2. Biochemistry 34: 1040-1049, 1995.
24. Sambrook J, Fritsch EF and Maniatis T, Molecular Cloning: A Laboratory Manual, 2nd Edn., Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989.
25. Dechert U, Adam M, Harder KW, Clark-Lewis I and Jirik F, Characterization of protein tyrosine phosphatase SH-PTP2. Study of phosphopeptide substrates and possible regulatory role of SH2 domains. J Biol Chem 269: 5602-5611, 1994.
26. Desmarais S, Govindarajan A, Ramachandran C, Zamboni R and Huang Z, Continuous spectrophotometric and fluormetric assays for protein tyrosine phosphatases using substituted aryl phosphates. FASEB J 96: 1347, 1995.
27. Zhang Z-Y, Maclean D, Thieme-Sefler AM, Roeske RW and Dixon JE, A continuous spectrophotometric and fluorimetric assay for protein tyrosine phosphatase using phosphotyrosine-containing peptides. Anal Chem 211: 7-15, 1993.
28. 2Pmp. Biochem Biophys Res Commun 204: 129-134, 1994.
29. Jia Z, Barford D, Flint AJ and Tonks NK, Structural basis for phosphotyrosine peptide recognition by protein tyrosine phosphatase 1B. Science 268: 1754-1758, 1995.
30. Fagerstam LG, Frostell-Karlsson A, Karlsson R, Persson B and onnberg I, Biospecific interaction analysis using surface plasmon resonance detection applied to kinetic, binding site and concentration analysis. J Chromatogr 597: 397-410, 1992.
31. Pharmacia Biosensor AB, BIAapplications Handbook. S-751 82 Uppsala, Sweden, 1994.
32. Swarup G, Cohen S and Garbers DL, Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate. Biochem Biophys Res Commun 107: 1104-1109, 1982.
33. Gresser MJ, Tracey AS and Stankiewicz PJ, The interaction of vanadate with tyrosine kinases and phosphatases. Adv Protein Phosphatases 4: 35-37, 1987.
34. Chasteen ND, (Ed.), Vanadium in Biological Systems. Kluwer Academic Publishers, Netherlands, 1990.
35. Guan KL and Dixon JE, Evidence for protein-tyrosine-phosphatase catalysis proceeding via a cysteine-phosphate intermediate. J Biol Chem 266: 17026-17030, 1991.
36. Cho H, Krisnaraj R, Kitas E, Bannwarth W, Walsh CT and Anderson KS, Isolation and structural elucidation of a novel phosphocysteine intermediate in the LAR protein tyrosine phosphatase enzymatic pathway. J Am Chem Soc 114: 7296-7298, 1992.
37. Singh R and Whitesides GM, A reagent for reduction of disulfide bonds in proteins that reduces disulfide bonds faster than does dithiothreitol. J Org Chem 56: 2332-2337, 1991.
38. Barford D, Protein phosphatase. Curr Opin Struct Biol 5: 728-734, 1995.
39. Barford D, Jia Z and Tonks NK, Protein tyrosine phosphatases take off. Nat Struct Biol 2: 1043-1053, 1995.
40. Zhang ZY and Dixon JE, Protein tyrosine phosphatases: Mechanism of catalysis and substrate specificity. Adv Enzymol 68: 1-36, 1994.
41. Zhang ZY, Wang Y and Dixon JE, Dissecting the catalytic mechanism of protein-tyrosine phosphatases. Proc Natl Acad Sci USA 91: 1624-1628, 1994.
42. Shaw CF, The protein chemistry of antiarthritic gold(I) thiolates and related complexes. Comments Inorg Chem 8: 233-267, 1989.
43. a of the active site cysteine and the function of the conserved histidine 402. Biochemistry 32: 9340-9345, 1993.
44. Streuli M, Krueger NX, Tsai AYM and Saito H, A family of receptor-linked protein tyrosine phosphatases in humans and Drosophila. Proc Natl Acad Sci USA 86: 8698-8702, 1989.
45. Champion GD, Graham GG and Ziegler JB, The gold complexes. Baillieres Clin Rheumatol 4: 491-534, 1990.
46. Gordon DA, Gold compounds. In: Rheumatology (Eds. Kelley WN, Harris ED, Ruddy S and Sledge CB), 3rd Edn., pp. 804-823. W. B. Saunders Co., Philadelphia, 1989.
47. Takahashi K, Griem P, Goebel C, Gonzalez J and Gleichmann E, The antirheumatic drug gold, a coin with two faces: Au(I) and Au(III). Desired and undesired effects on the immune system. Met Based Drugs 1: 483-496, 1994.
48. Griffin MM and Steven FS, Inhibition of trypsin and papain by sodium aurothiomalate mediated by exchange reactions. Br J Pharmacol 75: 333-339, 1982.